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Abstract
There is increasing epidemiologic evidence that arsenic exposure in utero is associated with adverse pregnancy outcomes
and may contribute to long-term health effects. These effects may occur at low environmental exposures but the underlying
molecular mechanism is not clear. We collected cord blood samples of 183 newborns to identify associations between
arsenic levels and birth anthropometric parameters in an area with very low arsenic exposure. Our core research aim was to
screen for transcriptional marks that mechanistically explain these associations. Multiple regression analyses showed that
birth weight decreased with 47 g (95% CI: 16–78 g) for an interquartile range increase of 0.99 mg/L arsenic. The model was
adjusted for child’s sex, maternal smoking during pregnancy, gestational age, and parity. Higher arsenic concentrations and
reduced birth weight were positively associated with changes in expression of the sFLT1 (soluble fms-like tyrosine kinase-1)
gene in cord blood cells in girls. The protein product of sFLT1 is a scavenger of vascular endothelial growth factor (VEGF) in
the extracellular environment and plays a key role in the inhibition of placental angiogenesis. In terms of fetal development,
inhibition of placental angiogenesis leads to impaired nutrition and hence to growth retardation. Various genes related to
DNA methylation and oxidative stress showed also changed expression in relation to arsenic exposure but were not related
to birth outcome parameters. In conclusion, this study suggests that increased expression of sFLT1 is an intermediate marker
that points to placental angiogenesis as a pathway linking prenatal arsenic exposure to reduced birth weight.
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Introduction
Arsenic (As) is a naturally occurring semi-metallic element that
can contaminate groundwater used for drinking and irrigation in
areas where it’s abundant. In Asia, millions of people are
chronically exposed to a high level of As in their drinking water
from wells drilled into As-rich geologic strata [1]. Concerns are
growing about inorganic As (iAs) in foods [2], especially in fruit
juices and in rice even in areas with low levels of naturally
occurring As. At high doses As increases risks of hyperkeratosis,
pigmentation changes, cardiovascular diseases, hypertension,
respiratory, neurological, liver and kidney disorders, as well as
diabetes mellitus. As a carcinogen it is known to cause bladder,
lung, and skin cancer (IARC, group I) [3]. iAs is metabolized by a
series of methylation reactions, converting it to methylarsonic acid
(MMA) and dimethylarsinic acid (DMA), which are excreted in
urine [4]. Mainly inorganic AsIII+ and MMA, are reactive, have
longer half-times in the tissues and considered more toxic.
iAs and its methylated metabolites pass the placenta. Concen-
trations measured in maternal blood correlate with concentrations
in cord blood [5]. It has been suggested that transplacental transfer
of As is driven by GLUT1 [6], which is known as the main
transplacental glucose transporter [7]. The main site of GLUT1
receptors is the syncytiotrophoblast [8], with a greater degree of
expression on the microvillous membrane compared to the basal
membrane. Less abundantly, GLUT1 is expressed in cytotropho-
blast cells and cells of the fetal vasculature [8]. When the
intervillous space - that lines the microvillous membrane - is filled
with maternal blood (2nd and 3th trimester of pregnancy), Arsenic
present in maternal blood can easily pass to the fetal circulation by
GLUT1 receptors. During the first 8–9 weeks of pregnancy, when
the spiral arteries are blocked by plugs of invading trophoblast
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cells, maternal blood flow to the intervillous space is restricted [9].
As a result, the intervillous space is not yet filled with maternal
blood but with a acellular fluid, derived from plasma and
endometrial glands [10]. It is not clear whether As can already
enter the intervillous space via plasma when the spiral arteries are
blocked, however an increased odds of child’s later intellectual
disability has been associated with specific exposure during this
period [11].
Levels of As in breast milk are very low, even in areas with
highly contaminated drinking water. In a study conducted in
Bangladesh [12], the As concentration in urine of infants whose
mothers reported exclusive breast-feeding ranged from 0.3 to
29 mg/L, whereas concentrations for those who reported partial
breast-feeding ranged up to 1520 mg/L. Thus, exclusive breast-
feeding protects the infant from exposure to As. The effects of As
in breast-fed infants are probably more attributable to the
intrauterine period of life as compared to the neonatal period,
but further studies are necessary to confirm this.
There is a fairly consistent picture of in utero or early-life
exposure to As at high levels in relation to elevated risk of adverse
birth outcome in areas where As concentrations in drinking water
that rise far above 40 mg/L (Table S1). However, epidemiological
data reporting the effects at the very low exposure end, i.e. below
the current WHO drinking water guidelines of 10 mg/L, are
currently scarce. The most recent studies investigating low ranges
of exposure reported that blood As levels were associated to
reduced birth weight [13,14] and birth length, and chest and head
circumference [14]. This triggered us to study whether the
reported associations could be confirmed in the Flemish popula-
tion of Belgium, in which As concentrations were even 10 times
lower as compared to both studies mentioned above. The majority
of human cohort studies is conducted in areas with elevated As
exposure and often lack individual exposure data and mechanis-
tically effect data which could lead to understand a causal role for
in utero As exposure in the development of later life disease.
Currently, the molecular mechanisms of action at higher As
levels are partly understood. Toxicity pathways that have been
suggested include DNA methylation [15–20], steroid receptor
signaling [21–24], and oxidative stress [23,25–29]. The mecha-
nistic insights are derived mainly from in vitro studies and animal
studies.
To the best of our knowledge, only one study exists in which
gene expression had been investigated in relation to As exposure at
the low-dose end, i.e. in New Hampshire (United States) [30]. The
median As concentration in household tap water was 0.36 mg/L
(IQR: 0.02–3.55). The expression of AQP9 was identified as a
potential placental biomarker for As exposure, while phospholi-
pase ENPP2 was positively associated with infant birth weight.
In the present paper we present the results of a cross sectional
study of the association between birth outcomes and biomarkers of
fetal exposure to As in a sample of mother–child pairs of the
general population of Flanders. The As levels in the cohort are all
very low. In addition, we measured gene expression of cord blood
cells as an intermediate biomarker to screen biological pathways
that may relate As exposure to the health outcome.
Materials and Methods
Ethics Statement
Written informed consent was provided by all mothers that
participated in this study. The mothers also signed the informed
consent on behalf of the children enrolled in the study. The study
protocol was approved by the ethical committee of the University
of Antwerp (Reference UA A08 09).
Study Population
The study was a part of a biomonitoring program for
environmental health surveillance in Flanders, Belgium [31].
Newborn-mother couples (n = 183) were recruited from the
general population of Flanders between August 2008 and July
2009 using a multistage sampling procedure. This population
consisted exclusively of uncomplicated liveborn singleton preg-
nancies. Ten maternities (two in each of the five Flemish
provinces) - at least 20 km apart from each other - were randomly
selected. All mothers that came to give birth were invited if they
lived at least 10 years in Flanders and were able to fill in a Dutch
questionnaire. The number of participants per province was
proportional to the number of inhabitants in that province (status
at 01/01/2006). The birth outcomes of interest (birth weight, head
circumference at birth and gestational age) were obtained via the
medical records of the maternities. Small for gestational age (SGA)
was calculated as birth weight less than the 10th percentile of birth
weight for each week of pregnancy defined by externally obtained
sex-specific reference weight curves 2001–2010 (Studiecentrum
voor Perinatale Epidemiologie). Covariate/confounder data of
individual health and lifestyle were obtained via questionnaires.
The characteristics of the study population (N=183) are presented
in Table S2).
Assessment of Arsenic Exposure
Total As exposure was measured in cord and maternal blood
samples. Cord blood was collected immediately after birth, while
maternal blood was collected during the mothers’ stay at the
maternity unit of the hospital. Arsenic concentration in whole
blood was measured by high resolution inductively coupled
plasma-mass spectrometry (ICP-MS) [32]. The limit of detection
(LOD) was 0.028 mg/L. For measurements below the LOD, we
assigned a value of half the LOD for analysis. The Pearson
correlation coefficient between the natural logarithm (Ln-trans-
formed) of the As values in cord and maternal blood was
determined. For the purpose of this study, statistical analysis was
done with As measured in cord blood, as it will be linked to
outcomes at birth, and As in maternal blood As was measured two
days after delivery.
Cord Blood Collection and Processing for Transcriptome
Profiling
The gene expression pattern of blood cells were analysed with
an Agilent microarray platform. Aliquots of cord blood (2–3 mL)
were collected in Tempus Blood Tubes (Applied Biosystems) as
quickly as possible after delivery. After collection, the content of
the tubes was mixed by inverting the tubes. Samples were kept at
4uC at the hospital (max 48 hours) and frozen at 220uC upon
arrival in our lab.
RNA Processing and Quantification
Total RNA was extracted from the blood samples using the
Tempus Spin RNA isolation kit (Applied Biosystems) according to
manufacturer’s instructions. RNA yields (13–160 mg/sample) were
measured using the NanoDrop Spectrophotometer (NanoDrop
Technologies). The integrity of the RNA was tested with capillary
gel-electrophoresis using RNA 6000 Chips (Agilent Technologies)
analyzed on the Agilent 2100 Bioanalyzer. RIN values ranged
from 7 to 9.6. Samples were stored at 280uC.
RNA Amplification and Labeling
Total RNA was amplified and labelled to generate comple-
mentary RNA (cRNA) labelled with cyanine (Cy)3-CTP using the
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Low Input Quick Amp Labelling (one color) kit (Agilent
Technologies) according to the manufacturer’s instructions. The
single-stranded, labelled cRNA was purified with Qiagen’s
RNeasy mini spin columns (Qiagen). Yield and specific activity
(dye-incorporation rate) were determined using the NanoDrop
spectrophotometer.
Microarray Hybridisation and Data Preprocessing
For each sample, 1.65 mg cRNA was hybridized per microarray
(4644 K Agilent Whole Human Genome, design 014850) during
17 h using the automated HS4800TM pro hybridization station
(Tecan), according to the manufacturer’s instructions. The arrays
were scanned with an Agilent scanner (G2565BA). The arrays
were subjected to a primary quality control using the Agilent
Feature Extraction Software (Version 10.7). For each feature on
the array, the software accurately determines the intensity
(gProcessedSignal, signal intensity derived from Cy3 fluorescent
dye), which were used as input for further processing and analysis
(Matlab, version R2012b). Normalization between arrays was
performed by means of quantile normalization upon logarithmic
transformation of the data (log2-scale). For sequences that are
replicated on the array, mean(log2(gProcessedSignal)) was calcu-
lated. Feature Extraction files include quality control parameters
for each of the sequences to assess reliability of the data. A reliable
sequence is defined as a sequence 1) of which the intensity is higher
than the feature noise level, 2) of which the intensity is below the
feature saturation level, 3) that is not a population outlier, 4) of
which the spot is uniform, and 5) of which the background is not
an outlier. This information was taken into account in the analysis
as described in section ‘Statistical analysis’.
RNA Processing and qPCR
For a subset of 30 samples RNA was reverse transcribed to
cDNA for qPCR analysis using a Roche LightCycler480. Prior to
cDNA synthesis, RNA samples were subjected to DNase treatment
(DNA-freeTM Kit, Invitrogen). cDNA synthesis and qPCR
reactions were performed as described previously [33]. PrimeTi-
meTM assays obtained from Integrated DNA Technologies were
used (Leuven, Belgium). Details of the 59 exonuclease PrimeTi-
meTM assays that were used are given in Table S3. qPCR data
processing was performed using the LightCycler software [33].
Stability of the reference genes (GNB2L1, RPLP0, RPL13A) was
verified using geNorm [34]. Gene expression changes were
analyzed using the qBase software [35]. Gene expression changes
were calculated as fold changes (FC) relative to the expression level
in one of the samples that was chosen as reference. Subsequently,
FCs were log2-transformed to enable comparison with microarray
data.
Statistical Analysis
For the identification of associations between As exposure and
adverse pregnancy outcome, database management and statistical
analyses were performed with SAS software version 9.3 (SAS
Institute Inc., Cary, NC, USA). Linear and logistic regression
analyses were used to quantify the effect on different growth
parameters associated with an interquartile range (IQR) increase
of the exposure to As. The exposure-response relations were
adjusted for a priori fixed known confounders, gender of the
newborn and smoking of the mother during pregnancy, that were
included irrespective of their significance level. Other influencing
factors (covariates) were included when significant at the 0.05 level
in the multiple regression model. The following covariates were
considered: gestational age (only for birth weight and head
circumference), maternal age, parity, stress/pressure during
pregnancy, maternal education level, (passive) smoking before
pregnancy, alcohol use before/during pregnancy, maternal height,
maternal body mass index (BMI), equivalent income, infections/
complication during pregnancy, use of folic acid during pregnancy
and caesarean section (only for gestational age). Effect modifica-
tion (interaction) was analyzed in models including main effects
and cross-product terms, and by doing stratified analyses. A p-
value ,0.20 for the effect of the cross-product was taken as an
indication of interaction. Assumptions of normality, constancy of
variance, independence (randomness), and linearity were checked
with informal diagnostic plots and formal tests (White’s General
test for constancy of variance [36], Kolmogorov-Smirnov test for
normality, and the lack of fit test for linearity [37]). Influence
statistics (residuals, leverage) were used to detect outliers and
influential data points, and regression models were fitted with and
without these influential outliers.
For the statistical analysis of the transcriptome data Matlab was
used, version 2012b. For our analysis we focused on a subset of
genes that were associated with intrauterine growth, DNA
methylation, oxidative stress, and As-related genes (Table S4).
Genes related to the first 3 processes were retrieved from the
Ingenuity Knowledge Base (Ingenuity Systems, www.ingenuity.
com), the list of As- related genes was obtained from a recent
publication [30]. We evaluated whether changes in the expression
of these molecules in cord blood cells can be related to 1) As
exposure, and/or 2) prenatal growth. For both comparisons we
evaluated on the subset of most extreme samples in the dataset.
With regards to As exposure, we tested whether ‘high’ exposed
samples show differences in expression as compared to ‘low’
exposed samples by independent two-sample t-test (two-sided,
unequal variance) for boys and girls separately. ‘High’ means As
level in cord blood higher than geometric mean plus standard
deviation (above 1.81: mg/L, nboys = 14, ngirls = 17), and ‘low’
smaller than geometric mean minus standard deviation (below
0.17 mg/L: nboys = 12, ngirls = 19). P-value below 0.05 was used as
a cut-off for statistical significance. We aimed to follow a similar
approach to select ‘high’ and ‘low’ birth weight babies. For this,
adjusting birth weight a priori for gestational age was necessary to
categorize the samples. A linear regression model - including a
quadratic term - was fitted separately for male en female babies
with gestational age as the independent variable and birth weight
as the outcome variable. For each individual, the ratio between
observed birth weight and the estimated birth weight at the same
gestational age was calculated. Following Ln-transformation of this
ratio, ‘high’ and ‘low’ birth weight samples were identified. ‘High
birth weight’ means Ln-transformed ratio above mean plus
standard deviation (nboys = 14, ngirls = 10), and ‘low birth weight’
smaller than mean minus standard deviation (nboys = 15,
ngirls = 14). Analogue to As exposure, we tested whether ‘low birth
weight’ samples show differences in expression as compared to
‘high birth weight’ samples for boys and girls separately. Following
a targeted approach (focused on a subset of genes among the
whole array), we decided to not correct for multiple testing.
Transcripts for which the microarray data were not reliable for all
samples being considered (according to the criteria mentioned
previously) were excluded from statistical analysis.
To demonstrate mediating effects of gene expression in the
association between As exposure and birth weight, a mediation
analysis was performed by the procedure described by Baron and
Kenny (1986) [38]. This method was applied to the markers
identified in microarray analysis (previous paragraph) that may
potentially link As exposure to birth weight. Applied to hypothet-
ical marker gene ‘X’ in mediating the association between As and
birth weight, a stepwise approach was followed in which the 4
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requirements of mediation [38] were verified by linear regression
(Figure 1). In the regression models, As exposure was categorized
in two groups, a group of ‘high’ exposure (level in cord blood
above geomean plus standard deviation, n = 31) and a group of
‘median or low’ exposure (the remaining samples, n = 152). For
birth weight, the continuous measure (expressed as gram birth
weight) was used. The following covariates were considered:
gender, gestational age, smoking during pregnancy, and parity.
Effect modification (interaction) was analyzed in models including
main effects and cross-product terms. To meet the four
requirements of mediation, birth weight (dependent variable)
should be associated with As exposure (independent variable)
(Model 1). Secondly, As exposure should be a significant predictor
of the expression of gene ‘X’ (the mediator) in cord blood cells. In
addition, the expression of gene ‘X’ should be a significant
predictor of birth weight (model 3). In the final step (model 4), it
must be confirmed that the expression of gene ‘X’ is a significant
predictor of birth weight, while controlling for As exposure. The
estimated change in birth weight related to As exposure (bAs) in
model 4 should be less compared to model 1 to demonstrate
mediation. Maximum evidence for mediation (full mediation)
occurs if by inclusion of the expression of gene ‘X’, bAs drops to
zero. In partial mediation bAs in model 4 is weaker, yet still
significant, compared to model 1. In that case, gene expression of
gene ‘X’ accounts for some – but not all – of the observed
association between As exposure and birth weight. The following
covariates were considered: gender, gestational age, smoking
during pregnancy, and parity. Effect modification (interaction) was
analyzed in models including main effects and cross-product
terms.
For confirmation of the expression of sFLT1 as measured with
microarray by use of qPCR, the correlation between both
measures was calculated for transcript NM_001159920. Input
values obtained from 30 samples were log2-transformed fold
changes relative to one of the samples (which was randomly
selected). Analogue, correlation between qPCR data obtained
from NM_001159920 and NM_001160030 (two transcript
variants of sFLT1 was calculated). For NM_001159920, the
difference in expression among ‘high’ and ‘low’ As exposure was
analyzed by independent two-sample t-test (two-sided, unequal
variance) and compared with differential expression measured by
microarray.
Results
Arsenic Exposure in Relation to Birth Outcome
Parameters
The geometric mean value of As in cord blood was 0.56 mg/L
(95% CI: 0.47–0.66 mg/L). The As levels ranged up to 14.4 mg/L,
with one value below the limit of detection (LOD) of 0.028 mg/L
(replaced by LOD/2), and an interquartile range of 0.99 mg/L. As
levels in maternal and cord blood were highly correlated (Pearson
correlation coefficient for Ln-transformed values r = 0.82 (p,
0.0001)). The correlation between both measures is visualized by
Figure 2.
Fourteen of the newborns (7.7%) were born as SGA-babies, the
gestational age ranged from 34 to 42 weeks with a median of 40
weeks (Table S2).
The multiple regression models showed a significant association
(p,0.05) between increasing As concentrations in cord blood and
an increased risk of SGA and lower birth weight. For an increase
of As cord blood levels with the interquartile range ( = 0.99 mg/L),
the risk for SGA babies increased with 38% (95% CI: 11–71%)
and birth weight decreased with 47 g (95% CI: 16–78 g)
(Table 1). The models were adjusted for child’s sex, smoking of
the mother during pregnancy, gestational age (only for birth
weight), and parity (only for birth weight). The model assumptions
were fulfilled, and the associations stayed statistically significant
after fitting the model without the influential outliers. No
statistically significant associations were found between As levels
in cord blood and head circumference at birth and gestational age.
The associations were not modified by sex when looking at the
cross-product term of sex with As levels (p-values ranged from
0.63–0.90). When doing stratified analyses, the associations
between As and birth outcomes were still statistically significant
in boys, but not in girls both for SGA and birth weight. Both
estimates were however in the same order, but due to power (only
about 90 individuals in each model) not statistically significant in
girls.
Expression of Genes Associated to ‘Embryonal Growth’
To identify molecules that might link the level of As exposure to
elevated risk on SGA, cord blood gene expression was analyzed.
After microarray quality control filtering, 158 different genes could
be annotated to the function ‘embryonal growth’ according the
Ingenuity Knowledge Base (Table S4). Figure 3 demonstrates
Figure 1. Mediation analysis. Microarray analysis was used to identify gene expression markers that are associated with both As exposure and
birth weight. Subsequently, a stepwise approach [38] was followed to investigate the mediating effects of the candidate gene expression markers in
the association between As exposure and birth weight by linear regression models. The method is described for hypothetical marker gene ‘X’. To
demonstrate mediation, four requirements must be met: Model 1) Birth weight (dependent variable) should be associated with As exposure
(independent variable); model 2) The expression of gene ‘X’ (mediator) should be associated with As exposure; model 3) Birth weight should be
associated with the expression of gene ‘X’; and model 4) the expression of gene ‘X’ should be a significant predictor of birth weight, while controlling
for As exposure. The estimated change in birth weight related to As exposure in model 4 should be less compared to model 1 to demonstrate partial
mediation, and drop to zero to demonstrate full mediation.
doi:10.1371/journal.pone.0092677.g001
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the potential of the transcripts to 1) discriminate the group of
‘high’ As exposure from the group of ‘low’ As exposure, and 2)
discriminate the group of ’low’ birth weight from ‘high’ birth
weight (adjusted for gestational age). The analysis was performed
for boys (Figure 3A) and girls (Figure 3B) separately. For each of
the sequences, the significance (2log10(PValue)) of differential
Figure 2. Correlation between the level of arsenic measured in cord blood and maternal blood. The Pearson correlation coefficient r
between the natural logarithm (ln-transformed) of the As values in cord blood (horizontal axis) and maternal blood (vertical axis) equals 0.82 (N= 177,
p-value,0.0001). The vertical and horizontal dotted line correspond to the geometric mean of cord blood and maternal blood As levels respectively.
For downstream analysis, the level of As in cord blood was categorized, i.e. ‘low As’ (filled squares): samples for which As level smaller than geometric
mean minus standard deviation; ‘high As’ (filled triangles): higher than geometric mean plus standard deviation; ‘median As’ (open circles): all
samples in between.
doi:10.1371/journal.pone.0092677.g002
Table 1. Multiple logistic (SGA) and linear (birth weight) regression analyses.
Birth outcome N Explanatory variable Unit Estimatea (95% CI) p-value
SGA 178 Cord blood As q0.99 mg/L 1.38 (1.11, 1.71) 0.0037
Sex of newborn boys vs. girls 1.13 (0.32, 3.97) 0.8448
Smoking during pregnancy yes vs no 2.91 (0.67, 12.71) 0.1562
Birth weight 177 Cord blood As q0.99 mg/L 247 (278, 216) 0.0033
Sex of newborn boys vs. girls 161 (45, 277) 0.0069
Smoking during pregnancy yes vs no 2111 (–288, 66) 0.2185
Gestational age q 1 week 216 (172, 261) ,0.0001
Parity 0 vs. 2+ 2184 (2327, 242) 0.0115
1 vs. 2+ 230 (2179, 120) 0.6942
0 vs. 1 2155 (2292, 217) 0.028
N= number of subjects; CI = Confidence Interval; SGA= Small for Gestational Age; As = Arsenic; q= increase with interquartile range; vs. = versus.
aInterpretation of the estimate: for SGA: the odds of having SGA is multiplied with the estimate ( = the odds ratio); for birth weight: the estimate is the increase/decrease
in weight.
doi:10.1371/journal.pone.0092677.t001
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regulation between ‘high’ and ‘low’ As is plotted on the horizontal
axis, and between ‘low’ and ‘high’ birth weight is plotted on the
vertical axis. Using quadrant visualisation, this plot also takes into
account the direction of regulation. The 1st quadrant is composed
of transcripts that show higher expression among the group of high
As and the group of SGA as compared to the group of low As and
the group of LGA, respectively. Making the same comparisons,
transcripts that show lower expression can be found in the 3rd
quadrant. Aiming to identify molecules that might link the level of
As exposure to elevated risk on SGA these quadrants are of special
interest, since the other 2 contain genes that show opposite
regulation of transcription in ‘high’ versus ‘low’ As exposure, as
compared to ‘low’ versus ‘high’ birth weight. The corresponding
gene symbol of transcripts with p-value smaller than 0.05 (dashed
threshold lines) in either ‘high’ versus ‘low’ As exposure or ‘low’
versus ‘high’ birth weight is included on the plot. Among girls, two
transcripts show stronger potential to link the level of As exposure
to elevated risk on SGA. One of them is upregulated in ‘high’ As
exposed and ‘low’ birth weight samples, i.e. a soluble transcript
variant of FLT1 (NM_001159920). The corresponding p-value for
differential expression between ‘high’ and ‘low’ As exposure equals
0.033, and 0.017 between ‘low’ and ‘high’ birth weight. The other
transcript (ACACA, Acetyl-CoA Carboxylase Alpha) is downregu-
lated in expression in ‘high’ As exposed and ‘low’ birth weight
samples. The corresponding p-value for differential expression
between ‘high’ and ‘low’ As exposure equals 0.032, and 0.009
between ‘low’ and ‘high’ birth weight. For boys, no transcripts
could be identified that show strong potential to link the level of As
exposure to elevated risk on SGA.
The expression of FLT1 was also measured by qPCR in a subset
of 30 samples. Different transcript variants of FLT1 exist, coding
for either the soluble isoform (sFLT1, NM_001159920,
NM_001160030, NM_001160031) or the transmembrane isoform
(mFLT1, i.e. NM_002019) of the protein. The data obtained for
the mFLT1 did not successfully pass quality control (lower
expression range, near detection limit). For sFLT1, reported
microarray data are restricted to NM_001159920 as the sequence
spotted on the microarray is specific for that variant. Use of qPCR
enabled us to measure two different variants of sFLT1, variant
NM_001160031 was not detectable. Microarray and qPCR data
of NM_001159920 correlated very well (Pearson correlation
coefficient r = 0.64, p = 1.33E204). The correlation between both
measures is visualized by Figure 4A. The subset of 30 samples
that was measured by qPCR included 15 samples of ‘high’ As
exposure and 15 samples of ‘low’ As exposure. The samples were
selected such that discrimination in expression as measured by
microarray was highly significant (P-value ‘high’ vs ‘low’ as
measured by qPCR was 8.2291E210). Measuring the expression
by qPCR, the difference between the two groups remained highly
significant (P-value = 3.2857E207). In addition, correlation be-
tween qPCR data obtained for NM_001159920 and
NM_001160030 was assessed (Figure 4B, Pearson correlation
coefficient r = 0.87, p = 2.55E204).
Figure 3. Genes associated to ‘embryonal growth’. This figure shows the potential of genes related to embryonal growth (N= 156) to link the
level of As exposure to decreased birth weight for boys (A) and girls (B) separately. For each of the sequences, the significance (2log10(PValue)) of
differential regulation between ‘high’ and ‘low’ As is plotted on the horizontal axis, and between ‘low’ and ‘high’ birth weight is plotted on the
vertical axis. The direction of regulation (up or down) is included in the plot. The 1st quadrant is composed of transcripts that show higher expression
among the group of high As and the group of low birth weight as compared to the group of low As and the group of high birth weight, respectively.
Making the same comparisons, transcripts that show lower expression can be found in the 3rd quadrant. The dashed threshold lines represent p-value
equal to 0.05. For transcripts of which the p-value is smaller than 0.05 in either one of the comparisons, the corresponding gene symbol is included in
the plot.
doi:10.1371/journal.pone.0092677.g003
sFLT1 Links Arsenic to Reduced Birth Weight
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e92677
Expression of Genes Associated to ‘DNA Methylation’
Analogue to the approach described in the previous paragraph,
genes involved in DNA methylation were analyzed (Figure S1).
The list of genes retrieved from the Ingenuity Knowledge Base can
be found in Table S4. The expression of MYC was positively
associated to the As level in boys (Figure S1A). In girls (Figure
S1B), respectively ARID4A and PLD6 were significantly up- and
downregulated, with increasing As levels. However, none of these
genes could be linked to decreased birth weight.
Expression of Genes Previously Associated with as
Exposure
To enable comparison with a recent publication [30], we also
focused on the expression of a panel of 9 As-related genes
(AKR1C3, ENPP2, HMOX1, LEP, NFE2L2, TYMS, AQP9, AS3MT,
and SLC39A2). They all successfully passed quality control filtering
(Table S4). None of them was found to be significantly different
(p-value ,0.05) in expression among ‘high’ versus ‘low’ exposure
or among ‘low’ versus ‘high’ birth weight.
Expression of Genes Associated to Oxidative Stress
Several studies indicate that oxidative stress may play a role in
As toxicity. A list of genes that are known to be involved in
oxidative stress responses was retrieved from the Ingenuity
Knowledge Base (Table S4). A volcano plot that includes p-
value and fold change (in ‘high As’ versus ‘low As’) for all 152 genes
for boys and girls separately can be found in Figure S2. Among
boys (Figure S2A), the expression of four genes differed between
‘high’ and ‘low’ As (GPX7, SNCA, YBX1, and MYC). In girls
(Figure S2B), BRCA1, MMP2, MMP9, PEMT, S100A12, SELK,
TAT, and VNN1 were differentially expressed. The direction of
regulation can be derived from the plot.
Mediating Effects of Gene Expression in the Association
between Arsenic Exposure and Birth Weight
Two genes showed changes in expression in response to As
exposure that could also be linked to reduced birth weight, i.e.
sFLT1 and ACACA. To explore to what extent the expression of
these genes mediates the association between As exposure and
birth weight, we verified whether the requirements to demonstrate
mediation were met according to Baron and Kenny, 1986 [38]
(Table 2). The association between As exposure and birth weight
which we demonstrated in table 1 remained significant after
categorizing the exposure level (Table 2, model 1), while
adjusting for the same set of parameters (gender, gestational age,
smoking during pregnancy, and parity). The interaction between
As exposure and gender was not significant (p = 0.21) and
therefore not included in the regression model. Birth weight
among ‘high’ exposed babies was 236 g lower (95% CI: 2397; 2
79 g, p = 0.0035) compared to low or median exposed babies.
Subsequently, we evaluated the expression of sFLT1 and ACACA in
function of As level, while adjusting for gender and gestational age.
Increased sFLT1 expression was significantly associated with As
exposure (p = 0.0196, Table 2, model 2). The interaction between
gender and As exposure was also evaluated, but was not significant
and therefore not considered. The log2 transformed fold change of
high exposed relative to low or median exposed babies was equal
to 0.30 (95% CI: 0.05; 0.55). Considering the expression of
ACACA, the significant difference that was demonstrated for girls
between ‘high’ and ‘low’ exposure could not be reproduced by
analyzing ‘high’ versus ‘low or median’ exposed (p = 0.3891).
Including the interaction between gender and As exposure did not
improve the result. Due to this, we limited the proceeding steps in
mediation analysis and the statistical output in table 2 to sFLT1. In
the next step, we evaluated birth weight in function of sFLT1,
Figure 4. qPCR analysis of sFLT1. A) Confirmation of gene expression of sFLT1 (NM_001159920) as measured by microarray with by qPCR for a
subset of 30 samples. For each sample, the expression of sFLT1 (was calculated as ratio to one given sample (reference sample, open square) and
subsequently logarithmically transformed (log2 scale). The Pearson correlation coefficient equals = 0.64 (p = 1.33E204). B) Correlation between two
transcript variants of sFLT1 (NM_001159920 and NM_001160030, N= 30). The pearson correlation coefficient equals 0.87 (p-value = 2.55E204).
doi:10.1371/journal.pone.0092677.g004
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while adjusting for gender, gestational age, smoking during
pregnancy, and parity (Table 2, model 3). The interaction
between sFLT1 expression and gender was significant (p = 0.0450)
and therefore also included. A significant reduction in birth weight
and sFLT1 expression was found for girls (p = 0.0061), but not for
boys (p = 0.9775). Duplication in sFLT1 expression in girls was
associated with a reduction in birth weight of 182 g (95% CI: 2
311; 252 g). In the final model (Table 2, model 4), we
demonstrate that sFLT1 was a significant predictor of birth weight
among the population of girls (p = 0.0118), while controlling for As
exposure. The reduction in birth weight associated with ‘high’ As
exposure was less pronounced (2219 g, 95% CI: 2376; 262 g) as
compared to the first model (2236 g, 95% CI: 2394; 279 g) in
which the effect of gene expression was not included. This
indicates that sFLT1 may be considered as a (partial) mediator in
the association between As exposure and reduced birth weight.
As a sensitivity analysis, it has been verified whether the
associations reported were influenced by maternal BMI and
pregnancy complications. Including BMI in each of the linear
regression models shown in table 2 did not influence the
significant findings that are reported. The fraction of the
population that reported pregnancy complications (i.e. high blood
pressure, pre-eclampsia, or gestational diabetes during pregnancy)
was very small (N= 8, table S2), therefore the associations reported
were not adjusted for these complications. It has been verified
whether the significant associations reported in the mediation
analysis (Table 2) were maintained 1) after adjusting for
pregnancy complications; and 2) when the participants reporting
one of these complications were excluded. By inclusion of this
variable in the models, the associations reported remained
significant. By exclusion of the participants reporting complica-
tions, the significant associations were also maintained.
Discussion
This study provides evidence that As exposure even at low
environmental levels is associated with birth anthropometric
parameters. Decrease in birth weight, independent of gestational
age, and an increased risk for babies born SGA was related to
increasing As concentrations in cord blood samples of newborn
babies. The association was observed at an exposure range which
is applicable to the exposure of ‘control subjects’ in other studies
(Table S1). Although maternal urinary As concentrations were
not analysed in our cohort, we have data of urinary levels of total
As and toxicologically relevant As (the sum of inorganic As,
monomethylarsonic acid (MMA), and dimethylarsinic acid
(DMA)) in a cohort from 101 women aged between 20 and 40
sampled in the same campaign. In this population, which is
representative for Flanders, the median levels of total As and
toxicological relevant As were respectively 16.2 mg/L (25th
percentile: 6.9 mg/L; 75th percentile: 30.1 mg/L) and 4.3 mg/L
(25th percentile: 2.9 mg/L; 75th percentile: 7.7 mg/L). The
observed effect on birth weight confirms findings at relatively
low levels [13,14]. However, the median As level in our cord blood
samples was 0.53 mg/L (25th percentile: 0.2 mg/L; 75th percentile:
1.2 mg/L) and is even about 10 times lower compared to both
studies mentioned. No significant associations were found between
As levels in cord blood and head circumference at birth and
gestational age. The latter could be an indication that the
associations between As and SGA and birth weight were not
mediated by effects on gestational age.
We tested whether changes in gene expression in cord blood
cells could reflect molecular links between As exposure and birth
outcomes. Specific gene panels were selected that were previously
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already associated with intrauterine growth retardation, As
exposure, or with potential mode of actions of As such as oxidative
stress and DNA methylation. Of these, two genes showed changes
in expression in response to As exposure that could also be linked
to the risk of SGA in our birth cohort, i.e. sFLT1 and ACACA.
Based on mediation analysis, sFLT1 is the most potential gene
expression marker to link As exposure to reduced birth weight.
The negative association between As exposure and birth weight;
and also the positive association between As and sFLT1 was
gender independent (as the interaction term between gender and
As was not significant). However, the effect of differential
expression of sFLT1 on birth weight was only significant in girls,
while there was absence of evidence for an association between
sFLT1 and birth weight for boys.
sFlt1 is a natural soluble factor, it is the truncated version of
VEGFR1 (or mFLT1) lacking transmembrane and intracellular
signaling domains. sFLT1 is a key molecule in inhibition of
placental angiogenesis, it inhibits angiogenesis by binding to free
forms of VEGF and PlGF [39]. In terms of fetal development,
inhibition of placental angiogenesis leads to impaired nutrition and
hence to growth retardation [40]. In a review by Tseng et al.,
chronic high level exposure to As has already been linked to
increased rates of pre-eclampsia [41]. In humans sFLT1 is used as
a biomarker for pre-eclampsia, but increased placental transcript
levels have also been demonstrated in normotensive pregnancy
with a SGA fetus [42]. This may indicate a common pathway
involved in the development of both conditions. The major source
of excess circulating sFLT1 protein in pre-eclampsia is the
placenta [39]. In 2005, Rajakumar et al. showed that peripheral
blood mononuclear cells comprise an extra-placental source of
sFLT1 that could potentially contribute to the pre-eclampsia
disease process [43]. Makris et al. investigated the relationship
between uteroplacental ischemia (UPI, an important trigger of
pre-eclampsia) and sFLT1 in non-human primates. They demon-
strated that induction of ischemia in the placenta also affects
sFLT1 mRNA expression in circulating cells not exposed directly
to ischemia [44]. Although the change in sFLT1 expression was
less than the rise in placental expression, it indicates that – at least
for sFLT1 - blood cells mRNA reflect transcriptional changes in
the placenta.
Disturbed regulation of placental angiogenesis confirms in
humans what has been demonstrated earlier in animal experi-
ments. Sodium arsenite caused spontaneous abortion in mice via
aberrant placental vasculogenesis and placental insufficiency [45].
In a broader framework, i.e. the cardiovascular system, As has
been shown to lead to cardiovascular diseases [46], including
hypertension [47], carotid atherosclerosis [48], and ischemic heart
disease [49] in non-pregnant residents from highly contaminated
areas. These vascular effects have been attributed to reduced NO
levels, which acts as a potent vasodilator. In vitro studies using
human umbilical vein endothelial cells confirmed that inorganic
arsenite or arsenate (100 mM) significantly suppressed the activity
of human eNOS [50]. It has been described that sFLT1 plays a
key role in regulation of eNOS [51]. As an angiogenic inhibitor, an
elevation in sFLT1 supresses eNOS expression. Considering the
low exposure range in our population, it is reasonable to
hypothesize that early molecular signs (sFLT1) of a cascade that
eventually leads to disturbance of the vascular system are present,
while downstream markers (such as eNOS) remain unchanged.
Although gender dichotomy in the mechanism of growth
restriction driven by sFLT1 has not been reported before, a very
recent study demonstrated sexual dimorphism in placental
function in severe pre-eclampsia [52]. In summary, they showed
that in pre-eclamptic pregnancies the placentas of males were
associated with significantly higher expression of inflammatory,
hypoxia and apoptotic molecules but reduced expression of a pro-
angiogenic marker compared to placentas of female fetuses. In a
mouse model of pre-eclampsia induced by sFLT1, significantly
higher blood pressure was demonstrated in male offspring that
were born to sFLT1–treated mothers as compared to control mice
[53]. The effect was not present in female offspring. Reduced
uterine perfusion in pregnant rats - that results in intrauterine
growth restricted (IUGR) offspring - has also been associated with
hypertension [54]. Male IUGR offspring remained hypertensive in
adulthood, whereas female IUGR offspring developed marked
elevations in mean arterial pressure prior to puberty but normalize
their blood pressure after puberty to levels comparable to female
control offspring. Ojeda et al. demonstrated that testosterone
contributes to the elevations in mean arterial pressure in adult
male IUGR offspring [55]. In studies that report gender
dichotomy in the context of pre-eclampsia or IUGR, the effects
are generally more pronounced in males. This is different from our
findings in which the association between birth weight and sFLT1
expression was restricted to female neonates. However, it suggests
that hormonal status may play a role in phenotypic modulation. In
the context of our results, it can be hypothesized that co-regulatory
gender dependent signals are involved in directing the sFLT1-
pathway towards its specific outcome. Accumulating data suggest
that As may act as an endocrine disruptor. It has been
demonstrated that monomethylated trivalent As species inhibit
binding of glucocorticoid (GR) and progesterone receptor (PR)
with their DNA response elements that are crucial to hormone-
driven gene transcription [21].
Our results indicate that sFLT1 is a partial mediator – and not a
full mediator - of the association between As exposure and birth
weight. This means that expression of sFLT1, accounts for some –
but not all – of the observed association. It implies that additional
factors are involved that could not be identified in our study. Gene
expression in cord blood was considered as a surrogate marker to
reflect adverse reactions in the tissues targeted by As exposure.
However, it cannot be assumed that gene expression measure-
ments in cord blood always reflect gene expression changes within
other tissues. This implies that potential mediators may be missed.
In addition, levels of regulation that were not covered in our study
– such as post transcriptional and epigenetic regulations – may
provide additional mediators to explain the association between As
exposure and reduced birth weight.
Conclusion
This study provides new insight in low-dose prenatal As toxicity.
Results of the 2nd Flemish Environment and Health Study showed
that the concentration of As in cord blood of newborns in the
present study was linked with reduced birth weight and a higher
risk of having a SGA baby, even though exposure in Flanders is
low compared to other regions. Impaired fetal growth is a risk
factor to develop metabolic problems later in life. Molecular data
indicate that impaired placental vascularisation, by upregulation of
sFLT1, might be a mechanistic basis that mediates the association
between As exposure and reduced birth weight.
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Figure S1 Genes associated to ‘DNA methylation’. This figure
shows the potential of genes related to DNA methylation to link
the level of As exposure to decreased birth weight for boys (A) and
girls (B) separately. For each of the sequences, the significance (2
log10(PValue)) of differential regulation between ‘high’ and ‘low’
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regulation (up or down) is included in the plot. The dashed
threshold lines represent p-value equal to 0.05. For transcripts of
which the p-value is smaller than 0.05 in either one of the
comparisons, the corresponding gene symbol is included in the
plot.
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Figure S2 Genes associated to ‘Oxidative stress’. The volcano
plot includes the p-value and fold change (in ‘high Arsenic’ versus
‘low Arsenic’) of genes related to oxidative stress (N=152) for boys
(A) and girls (B) separately. The dashed treshold lines correspond
to p-value equal to 0.05. For transcripts of which the p-value is
smaller than 0.05, the corresponding gene symbol is included in
the plot.
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general population of Dalian. Biol Trace Elem Res 149:10-15. 3.
Hopenhayn C, Ferreccio C, Browning SR, Huang B, Peralta C,
Gibb H, Hertz-Picciotto I (2003) Arsenic exposure from drinking
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(2005) Chronic arsenic exposure and adverse pregnancy outcomes
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